Always consult a licensed healthcare provider before starting any new medication or weight management program
Buse JB, Bergenstal RM, Glass LC, et al
A key study worth noting here is the STEP 1 trial, published in the New England Journal of Medicine, which demonstrated that once-weekly semaglutide 2.4mg produced 14.9 percent mean weight loss versus 2.4 percent with placebo in adults with obesity or overweight with at least one weight-related condition
By Age Group: Geriatric Acceleration Reflects Demographic Transition Adults retained 60.03% of 2025 demand, but the cohort aged 65 is forecast to surge at 4.67% CAGR, raising new requirements for polypharmacy management and cognitive-friendly devices
Wed be happy to walk you through your options
This information is for educational purposes and is not medical advice